Chemotherapy of non-small cell lung cancer

Clinical trials at the Memorial Sloan-Kettering Cancer Center

Richard J. Gralla, R. E. Wittes, E. S. Casper, D. P. Kelsen, E. Cvitkovic, G. B. Magill, S. E. Krown, R. B. Golbey

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Bronchogenic carcinoma is one of the most difficult and pressing problems in cancer therapy. Overall survival of 799 primary cases at Memorial Sloan-Kettering Cancer Center was 7.8%, reflecting the advanced nature of most lung cancer at the time of presentation and the inadequacy of current local therapies as potential cures. The need for effective systemic therapy having acceptable toxicity is obvious. From 1972 to 1975, four combination drug regimens were tested at the Center: MAV, MFC, CAMF, and VAB. Despite the lack of significant responses, the median survival was 2.5 to 6 months. A subsequent study of the effect of high doses of cyclophosphamide, followed by high doses of methotrexate with leukovorin rescue, produced significant toxicity; partial responses were seen in 5/20 patients. Other agents tested have included pyrazofurin, vindesine, chlorozotocin, PCNU, PALA, m-AMSA, and interferon. Only vindesine has shown promise. Recent trials of cisplatin (DDP) in combination with vindesine have been encouraging. Eighty-one patients with measurable inoperable non-small cell lung cancer have been treated with this combination. Toxicity has been easily managed. Complete or partial responses have been demonstrated in 43 percent of 35 patients. Duration of response has been significantly greater for patients receiving high-dose DDP as compared to low-dose DDP. Addition of cyclophosphamide to the regimen appeared to offer no obvious advantages. Future studies include a clinical trial of the DDP-vindesine combination in the adjuvant setting.

Original languageEnglish (US)
Pages (from-to)667-673
Number of pages7
JournalWorld Journal of Surgery
Volume5
Issue number5
DOIs
StatePublished - Sep 1981
Externally publishedYes

Fingerprint

Vindesine
Non-Small Cell Lung Carcinoma
Clinical Trials
Drug Therapy
pyrazofurin
NSC 224131
chlorozotocin
Cyclophosphamide
Neoplasms
Amsacrine
Survival
Leucovorin
Bronchogenic Carcinoma
Drug Combinations
Methotrexate
Interferons
Cisplatin
Lung Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Gralla, R. J., Wittes, R. E., Casper, E. S., Kelsen, D. P., Cvitkovic, E., Magill, G. B., ... Golbey, R. B. (1981). Chemotherapy of non-small cell lung cancer: Clinical trials at the Memorial Sloan-Kettering Cancer Center. World Journal of Surgery, 5(5), 667-673. https://doi.org/10.1007/BF01657925

Chemotherapy of non-small cell lung cancer : Clinical trials at the Memorial Sloan-Kettering Cancer Center. / Gralla, Richard J.; Wittes, R. E.; Casper, E. S.; Kelsen, D. P.; Cvitkovic, E.; Magill, G. B.; Krown, S. E.; Golbey, R. B.

In: World Journal of Surgery, Vol. 5, No. 5, 09.1981, p. 667-673.

Research output: Contribution to journalArticle

Gralla, RJ, Wittes, RE, Casper, ES, Kelsen, DP, Cvitkovic, E, Magill, GB, Krown, SE & Golbey, RB 1981, 'Chemotherapy of non-small cell lung cancer: Clinical trials at the Memorial Sloan-Kettering Cancer Center', World Journal of Surgery, vol. 5, no. 5, pp. 667-673. https://doi.org/10.1007/BF01657925
Gralla, Richard J. ; Wittes, R. E. ; Casper, E. S. ; Kelsen, D. P. ; Cvitkovic, E. ; Magill, G. B. ; Krown, S. E. ; Golbey, R. B. / Chemotherapy of non-small cell lung cancer : Clinical trials at the Memorial Sloan-Kettering Cancer Center. In: World Journal of Surgery. 1981 ; Vol. 5, No. 5. pp. 667-673.
@article{0bcf16ed47f248e8a36adb745a318b27,
title = "Chemotherapy of non-small cell lung cancer: Clinical trials at the Memorial Sloan-Kettering Cancer Center",
abstract = "Bronchogenic carcinoma is one of the most difficult and pressing problems in cancer therapy. Overall survival of 799 primary cases at Memorial Sloan-Kettering Cancer Center was 7.8{\%}, reflecting the advanced nature of most lung cancer at the time of presentation and the inadequacy of current local therapies as potential cures. The need for effective systemic therapy having acceptable toxicity is obvious. From 1972 to 1975, four combination drug regimens were tested at the Center: MAV, MFC, CAMF, and VAB. Despite the lack of significant responses, the median survival was 2.5 to 6 months. A subsequent study of the effect of high doses of cyclophosphamide, followed by high doses of methotrexate with leukovorin rescue, produced significant toxicity; partial responses were seen in 5/20 patients. Other agents tested have included pyrazofurin, vindesine, chlorozotocin, PCNU, PALA, m-AMSA, and interferon. Only vindesine has shown promise. Recent trials of cisplatin (DDP) in combination with vindesine have been encouraging. Eighty-one patients with measurable inoperable non-small cell lung cancer have been treated with this combination. Toxicity has been easily managed. Complete or partial responses have been demonstrated in 43 percent of 35 patients. Duration of response has been significantly greater for patients receiving high-dose DDP as compared to low-dose DDP. Addition of cyclophosphamide to the regimen appeared to offer no obvious advantages. Future studies include a clinical trial of the DDP-vindesine combination in the adjuvant setting.",
author = "Gralla, {Richard J.} and Wittes, {R. E.} and Casper, {E. S.} and Kelsen, {D. P.} and E. Cvitkovic and Magill, {G. B.} and Krown, {S. E.} and Golbey, {R. B.}",
year = "1981",
month = "9",
doi = "10.1007/BF01657925",
language = "English (US)",
volume = "5",
pages = "667--673",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Chemotherapy of non-small cell lung cancer

T2 - Clinical trials at the Memorial Sloan-Kettering Cancer Center

AU - Gralla, Richard J.

AU - Wittes, R. E.

AU - Casper, E. S.

AU - Kelsen, D. P.

AU - Cvitkovic, E.

AU - Magill, G. B.

AU - Krown, S. E.

AU - Golbey, R. B.

PY - 1981/9

Y1 - 1981/9

N2 - Bronchogenic carcinoma is one of the most difficult and pressing problems in cancer therapy. Overall survival of 799 primary cases at Memorial Sloan-Kettering Cancer Center was 7.8%, reflecting the advanced nature of most lung cancer at the time of presentation and the inadequacy of current local therapies as potential cures. The need for effective systemic therapy having acceptable toxicity is obvious. From 1972 to 1975, four combination drug regimens were tested at the Center: MAV, MFC, CAMF, and VAB. Despite the lack of significant responses, the median survival was 2.5 to 6 months. A subsequent study of the effect of high doses of cyclophosphamide, followed by high doses of methotrexate with leukovorin rescue, produced significant toxicity; partial responses were seen in 5/20 patients. Other agents tested have included pyrazofurin, vindesine, chlorozotocin, PCNU, PALA, m-AMSA, and interferon. Only vindesine has shown promise. Recent trials of cisplatin (DDP) in combination with vindesine have been encouraging. Eighty-one patients with measurable inoperable non-small cell lung cancer have been treated with this combination. Toxicity has been easily managed. Complete or partial responses have been demonstrated in 43 percent of 35 patients. Duration of response has been significantly greater for patients receiving high-dose DDP as compared to low-dose DDP. Addition of cyclophosphamide to the regimen appeared to offer no obvious advantages. Future studies include a clinical trial of the DDP-vindesine combination in the adjuvant setting.

AB - Bronchogenic carcinoma is one of the most difficult and pressing problems in cancer therapy. Overall survival of 799 primary cases at Memorial Sloan-Kettering Cancer Center was 7.8%, reflecting the advanced nature of most lung cancer at the time of presentation and the inadequacy of current local therapies as potential cures. The need for effective systemic therapy having acceptable toxicity is obvious. From 1972 to 1975, four combination drug regimens were tested at the Center: MAV, MFC, CAMF, and VAB. Despite the lack of significant responses, the median survival was 2.5 to 6 months. A subsequent study of the effect of high doses of cyclophosphamide, followed by high doses of methotrexate with leukovorin rescue, produced significant toxicity; partial responses were seen in 5/20 patients. Other agents tested have included pyrazofurin, vindesine, chlorozotocin, PCNU, PALA, m-AMSA, and interferon. Only vindesine has shown promise. Recent trials of cisplatin (DDP) in combination with vindesine have been encouraging. Eighty-one patients with measurable inoperable non-small cell lung cancer have been treated with this combination. Toxicity has been easily managed. Complete or partial responses have been demonstrated in 43 percent of 35 patients. Duration of response has been significantly greater for patients receiving high-dose DDP as compared to low-dose DDP. Addition of cyclophosphamide to the regimen appeared to offer no obvious advantages. Future studies include a clinical trial of the DDP-vindesine combination in the adjuvant setting.

UR - http://www.scopus.com/inward/record.url?scp=0019769264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019769264&partnerID=8YFLogxK

U2 - 10.1007/BF01657925

DO - 10.1007/BF01657925

M3 - Article

VL - 5

SP - 667

EP - 673

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 5

ER -